CHEM E-120 Harvard University Extension School Stimulants 1.
CHEM E-120 Harvard University Extension School
description
Transcript of CHEM E-120 Harvard University Extension School
CHEM E-120Harvard University Extension School
Neurodegenerative DisordersAlzheimer’s Disease
April 6, 2011
14/6/11 CHEM E-120
Alzheimer’s DiseaseMost prevalent of the neurodegenerative diseasesAffects ~ 15-20 million individuals worldwideAge onset ~ 60 – 65 years, risk of developing Alzheimer’s doubles every 5 years after age 65 with a 50% chance after age 85.8th leading cause of death
Main clinical symptom is dementia
early memory impairmentepisodic memoryprogressive decline in executive function – reasoning, etcdrastic alterations in personality – aggressive behavior
DSM-IV classifies several forms of dementiaNo diagnostic tool premortem except clinical dementia rating (CDR)
Postmortem analysis is characterized by the identification of neurofibrillary tangles (NFT) and amyloid plaques.
24/6/11 CHEM E-120
Cholinergic Hypothesis - AD
3
Based on finding reduced activity of choline acetyltransferase activity and loss of cholinergic neurons in the forebrain. Reduction in amount of acetylcholine.
Cholinergic system appears important in
cognitive function: attention, memorynoncognitive function: depression, psychosis, aggression, sleep
Acetylcholine (ACh) binds to muscarinic receptors and nicotinic (nAChR) Na+ channels.
4/6/11 CHEM E-120
HON
Choline
choline acetyltransferase
acetyl-S-CoA ON
O
acetylcholine
4
Neurotransmitters - Acetylcholine
mnemonic functionneurofibrally tanglesappear here firstin early satge AD
4/6/11 CHEM E-120
5
Loss of ACh
How to increase it?
1. Inhibition of ACHE2. M1 agonist (stimulates cognitive function)3. NAChR agonists α4β2 agonist
predominate NACh subunit in brainpartial agonist Varenicline
(7)5 agonist inc Ca2+ permeabilityagonist increase cognition
4. 5-HT1A antagonist increase ACh and glutamate
Comprehensive Medicinal Chemistry IIChapter 6.084/6/11 CHEM E-120
Mediciation Development Alzheimer’s Disease
6
1. Acetylcholineesterase inhibitors (4 approved for use)
Tacrine (Cognex)Donepezil (Aricept)Rivastigmine (Exelon)Galantamine (Razadyne, Reminyl)
2. NMDA noncompetitive antagonist (Approved)
Memantine (Namenda)reduces Ca2+ influx into neurons, excess Ca2+ is cytotoxic
3. β-Secretase inhibitors4. GSK-3 inhibitors (Annual Reports in Med. Chem. 2010, 44, 35. 5HT1A antagonists
4/6/11 CHEM E-120
7
AcetylcholinesteraseAcetylcholinesterase (ACHE) is a serine esterase enzyme
ACHE has an anionic binding site which attracts the positively charged quaternary ammonium group of ACH. A serine then attacks and cleaves the ester. This is an example of general base catalysis.
4/6/11 CHEM E-120
ON
O
NH
OO
O
Glu (E) 327
NH O
O H
HNO
NHN
His (H) 440
Ser (S) 200
8
van der Waals surface map of acetylcholine in active site of AChE
Phe297
Phe295
vs aliphaticin BChE
catalytic triad
inhibitor binding site
Glu202 quat siteBasic Neurochemistry p. 1954/6/11 CHEM E-120
9Acta Biologica Hungarica 54 (2), pp. 183–189 (2003)4/6/11 CHEM E-120
Donepezil - Aricept
10
Approved in 1997
Annual Reports in Medicinal Chemistry 1998, 33, 332Jpn. J. Pharmacol. 89, 7 – 20 (2002)
4/6/11 CHEM E-120
11
Discovery of Donepezil
Jpn. J. Pharmacol. 89, 7 – 20 (2002)
1 found through random screeningprepared about 700 analogs
benzylpiperizine to benzylpiperidine
replacement of ether
4 poor bioavailability and short durationof action
4/6/11 CHEM E-120
12
Discovery of Donepezil
7 replace amide by ketone
6 cyclic amide better inhibitionthan 5
leads to 8IC50 less than 4 but longer duration of action
SAR
4/6/11 CHEM E-120
13
Discovery of Donepezil
ring size
carbonyl
4/6/11 CHEM E-120
14
Discovery of Donepezil
p-methoxy4/6/11 CHEM E-120
15
Discovery of Donepezil
4/6/11 CHEM E-120
16
Discovery of Donepezil
location and number of N’s
4/6/11 CHEM E-120
17
Discovery of Donepezil
pKa!
4/6/11 CHEM E-120
18
Discovery of Donepezil
oral ID50 = 2.6 mg/kg
Tacrine oral ID50 = 9.5 mg/kg
4/6/11 CHEM E-120
19
Discovery of Donepezil
equivalent to Meynert nucleus in humans
move from light to dark chamber (foot shock)learn: avoid dark chamber
no le
arni
ng
MS cholinergic projections to hippocampus
4/6/11 CHEM E-120
20
Discovery of Donepezil
4/6/11 CHEM E-120
21
Discovery of DonepezilResult of J-CGIC
4/6/11 CHEM E-120
22
Structure March 1999, 7:297–307 π-π stacking
4/6/11 CHEM E-120
23
Structure March 1999, 7:297–307
4/6/11 CHEM E-120
Amyloid Plaque Formation
24
Insoluble, neurotoxic, protein clusters formed from Amyloid Precursor Protein (APP)
770 AA AA669 Asp
BACE β-secretase
AA669AA770
Β-CFT
γ-secretase
Aβ – β-amyloid1-40(42)
AChEfibril
peripheral siteof AChE
N terminusextracellular
C terminusintracellular
4/6/11 CHEM E-120
BACE Inhibitors 2-Amino-3,4-dihydroquinazolines
25
J. Med. Chem. 2007, 50, 4261 Johnson & Johnson
High-throughput hit from a screen of their corporate compoundcollection
4/6/11 CHEM E-120
BACE - 2-Amino-3,4-dihydroquinazolines
26
First obtained a X-ray crystal of 1 bound to BACE-1
1 forms a U shaped conformation in active site4/6/11 CHEM E-120
BACE - 2-Amino-3,4-dihydroquinazolines
274/6/11 CHEM E-120
5-HT1A Antagonists
28
It has been suggested that the serotonergic system may be hyperactive in AD as a result of enhanced turnover of serotonin. This will ultimately result in the reduction of activity of cortical pathways by the binding of serotonin to autoreceptors on presynaptic neurons.
It has been found that 5-HT1A antagonists can facilitate glutamatergic activity and cholinergic activity which leads to a reduction in cognitive deficits.
The Potential Utility of 5-HT1A Receptor Antagonists in the Treatment of Cognitive Dysfunction Associated with Alzheimer’s Disease Current Pharmaceutical Design, 2002, 8, 139-145
Lecozatan – Selective 5-HT1A Antagonist
4/6/11 CHEM E-120
WAY100135 – Selective 5-HT1A Antagonist
29
Arylpiperazines reported to be high-affinity 5-HT1A ligands (JMC 1988, 31, 1968)
Eur. J. Pharmacol. 1988, 154, 339
In 1993 WAY100135 was reported as the first true selective antagonist of 5-HT1A
Eur. J. Pharmacol. 1993, 237, 283
4/6/11 CHEM E-120
WAY100135 – Selective 5-HT1A AntagonistEvidence for presynaptic antagonist activity (autoreceptor)
30
Drug ID50 (μg/kg i.v.)
8-OH-DPAT (agonist) 1.9BMY7378 (partial agonist) 12NAN-190 (partial agonist) 16MDL73005EF (“) 81(±)WAY100135 >2500(+)WAY100135 >600 (-)WAY100135 >1000
serotonin at 5-HT1A presynaptic inhibits firing
inhibitory effect serotonin is blocked
4/6/11 CHEM E-120
WAY100135 – Selective 5-HT1A AntagonistEvidence for presynaptic antagonist activity
31
The 5-HT1A agonist 8-OH-DPAT induces hypothermia in mice.
An antagonist should prevent this in a dose-dependent manner
(±)WAY100135 ED50 = 2.0 mg/kg s.c.(+)WAY100135 ED50 = 1.5 mg/kg s.c. (-)WAY100135 ineffective up to 30 mg/kg
4/6/11 CHEM E-120
WAY100135 – Selective 5-HT1A AntagonistEvidence for postsynaptic antagonist activity
32
5-CT is a 5-HT1A
agonist that:
Inhibits the electricallystimulated contractionof muscle
rightward shift that isindicative of antagonism
4/6/11 CHEM E-120
WAY100135 – Selective 5-HT1A AntagonistEvidence for postsynaptic antagonist activity
33
The 8-OH-DPAT syndromeDue to 5-HT activation
Extended flat body postureForepaw treadingHyperlocomotion
(±)(+)
(-)
4/6/11 CHEM E-120
WAY100635
34
Eur. J. Pharmacol. 1995, 281, 81-88
Drug IC50 (nM) pA2 (5-CT) ED50 (antag. Induced hypothermia)
(±)WAY100135 34 7.2 2.5 mg/kg(+)WAY100135 15 (-)WAY100135 437
WAY100635 1.35 9.7 0.01 mg/kg
>100 fold selective vs other 5-HT receptors and 35 other receptors/transporters
4/6/11 CHEM E-120
Lecozatan – Selective 5-HT1A Antagonist
35
WAY-100635 lacked bioavailability.
Modification of the amide portion and N-phenyl portion.
4/6/11 CHEM E-120
Lecozatan – Selective 5-HT1A Antagonist
36
Though not the most potentin vitro antagonist, 11c showedmost potency in vivo
Rats trained to respond to fixed ratio-30 schedule offood presentation to receive afood pellet.
Agonist 8-OH-DPAT reducesresponse rate.
4/6/11 CHEM E-120
Lecozatan – Selective 5-HT1A Antagonist
37
J. Pharmacology and Experimental Therapeutics 2005, 314, 12744/6/11 CHEM E-120
Lecozatan – Selective 5-HT1A Antagonist
38
In vivo microdialysisin conscious rats
4/6/11 CHEM E-120
Lecozatan – Selective 5-HT1A Antagonist
39
Time dependent increase in glutamate levels in dentate gyrus by in vivo microdialysis
4/6/11 CHEM E-120
Lecozatan – Selective 5-HT1A Antagonist
40
Time dependent increase in acetylcholine levels in hippocampus by in vivo microdialysis
4/6/11 CHEM E-120
Lecozatan – Selective 5-HT1A Antagonist
41
Lecozotan enhances cognitive function in the aged rhesus monkey as assessed by DMTS(delayed matching-to-sample) performance efficiency.
16% @ 1.0 mg/kg
4/6/11 CHEM E-120
Lecozatan – Selective 5-HT1A Antagonist
42
Nature Clinical Pharmacology and Therapeutics 2008, 83, 86
binding of 11C-WAY-100635
4/6/11 CHEM E-120
Lecozatan – Selective 5-HT1A Antagonist
43
Nature Clinical pharmacology and Therapeutics 2008, 83, 86
Study shows Lecozotan is readily absorbed into the brain and binds to 5-HT1A receptors regardless of age and is not affected by AD being present
4/6/11 CHEM E-120